NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)
Yahoo FinanceApr 26 04:12 ET
Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Innate Pharma SA (OtherIPHYF) and Neumora Therapeutics, Inc. (NMRA)
TipRanksApr 17 04:10 ET
Innate Pharma's NK Cell Engager Enters Phase 2 Trials
TipRanksApr 15 21:00 ET
Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio
Yahoo FinanceApr 15 10:07 ET
Express News | Innate Pharma Advances Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing To Phase 2 For Blood Cancer Patients
Moomoo 24/7Apr 15 01:47 ET
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") will hold its Annual General Meeting of Shareholders ("AGM") at 10:30 a.m. CEST on May 23, 2024 in its headquarters, 117 avenue de
BusinesswireApr 15 01:00 ET
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Yahoo FinanceApr 10 12:00 ET
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4 In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows anti-tumor
BusinesswireApr 10 01:00 ET
Innate Pharma Announces Its Participation in Upcoming Investor Conference
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed
BusinesswireApr 9 01:00 ET
Express News | Innate Pharma Says It Filed Its 2023 Universal Registration Document (Document D'enregistrement Universel) And 2023 Annual Report On Form 20-F
Moomoo 24/7Apr 5 05:15 ET
Innate Pharma Files Its 2023 Universal Registration Document (Document D'enregistrement Universel) and 2023 Annual Report on Form 20-F
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News:Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the filing of its 2023 Universal Registration Docum
BusinesswireApr 5 03:34 ET
Innate Pharma's Growth at Risk: The Challenge of Relying on External Partners and a Lean Team
TipRanksApr 5 02:01 ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. The company's market cap stands at $24.9 million. Kineta (NASDAQ:KA) shares rose 8.46% to
BenzingaApr 3 16:31 ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersGalera Therapeutics (NASDAQ:GRTX) shares moved upwards by 62.8% to $0.23 during Monday's pre-market session. The market value of their outstanding shares is at $12.3 million. As per the news, t
BenzingaApr 1 08:08 ET
Innate Pharma SA: A Balanced Hold Rating Amidst Clinical Setbacks and Cautious Optimism
TipRanksMar 26 16:45 ET
Analysts Offer Insights on Healthcare Companies: Innate Pharma SA (OtherIPHYF), Medios AG (OtherMEDOF) and Tecan Group AG (OtherTCHBF)
TipRanksMar 22 21:40 ET
Express News | HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target
Moomoo 24/7Mar 22 06:26 ET
Innate Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 377.18% HC Wainwright & Co. → $11.5 Reiterates Buy → Buy 11/15/2023 377.18% HC Wainwright & Co.
BenzingaMar 22 06:18 ET
Earnings Call Summary | Innate Pharma(IPHA.US) Q4 2023 Earnings Conference
The following is a summary of the Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript:Financial Performance:Innate Pharma reported cash, cash equivalents, short-term investments and financial a
moomoo AIMar 21 16:00 ET · Conference Call
Innate Pharma S.A.: Financial Overview and Gains
TipRanksMar 21 10:27 ET
No Data
No Data